Skip to main content

MoneyWorks4Me

GlaxoSmithkline Pharma decides to enter into India-specific alliance

04 Feb 2013 Evaluate

Multinational drug-maker, GlaxoSmithkline Pharmaceuticals has decided to enter into India-specific alliance, which will be for a product that is a new area for the company. With this decision to bring in niche products from other drug-majors through in-licensing deals, the company aims to expand the operations locally.

The entity’s existing alliances in the local market include ones with Daiichi-Sankyo on hypertensive Olmesartan Medoxomil, and with Astellas on anti-fungal drug Micafungin.

Peers
Company Name CMP
Sun Pharma. Inds. 1866.95
Dr. Reddys Labs. 1380.00
Cipla 1394.00
Lupin 1972.50
Zydus Lifesciences 1189.00
View more..